Scarica l'app Stockscreener
1.645
2.08%
-0.035
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.68
Aprire:
$1.69
Volume 24 ore:
1.57M
Relative Volume:
1.15
Capitalizzazione di mercato:
$97.59M
Reddito:
-
Utile/perdita netta:
$-144.01M
Rapporto P/E:
-0.4102
EPS:
-4.01
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
-38.39%
1M Prestazione:
-14.77%
6M Prestazione:
-6.00%
1 anno Prestazione:
-84.74%
Intervallo 1D:
$1.60
$1.7143
Intervallo di 1 settimana:
$1.60
$2.01
Portata 52W:
$1.2905
$12.85
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
1599 INDUSTRIAL ROAD, SAN CARLOS
Confronta BMEA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.64 | 118.78M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.54 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.41 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-28 | Iniziato | Jefferies | Buy |
| 2025-06-03 | Ripresa | Piper Sandler | Overweight |
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Real time pattern detection on Biomea Fusion Inc. stockWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com
Is Biomea Fusion Inc. meeting your algorithmic filter criteriaJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Biomea Fusion Inc. stock retracement – recovery analysisWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Should you wait for a breakout in Biomea Fusion Inc.Portfolio Value Summary & Fast Exit and Entry Strategy Plans - newser.com
Biomea Fusion (NASDAQ:BMEA) Trading Up 6.5%What's Next? - MarketBeat
Tools to assess Biomea Fusion Inc.’s risk profileMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Does Biomea Fusion Inc. fit your quant trading model2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
What analysts say about Biomea Fusion Inc stockBollinger Bands Signals & Free Unmatched Market Gains - earlytimes.in
Why Biomea Fusion (BMEA) Is Up After Positive Diabetes Data and $25M Equity Raise – And What’s Next - Yahoo Finance
Biomea Fusion Announces Positive Phase II Study Results - MSN
Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st
Nasdaq Tumbles 200 Points; Trilogy Metals Shares Spike Higher - Benzinga
Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups - insights.citeline.com
Biomea’s ‘durable’ menin inhibitor advancing in hard-to-treat diabetes - BioWorld MedTech
Biomea Fusion: Surging On Data, Sinking On FundingI'm On The Sidelines - Seeking Alpha
Traders Purchase High Volume of Biomea Fusion Call Options (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study - inkl
Dow Jumps Over 100 Points; McCormick Earnings Top Views - Benzinga
Biomea Fusion announces pricing of public offering of securities - MSN
Biomea Fusion prices $25 million public offering of shares and warrants - Investing.com
Biomea Fusion plunges on $25 mln stock-and-warrants offering - TradingView
Biomea Fusion Announces Pricing of Public Offering of Securities - The Manila Times
D. Boral Capital Maintains Biomea Fusion (BMEA) Buy Recommendation - Nasdaq
$25M Offering: Biomea Fusion Prices 11.2M Shares & Warrants at $2.05 — Closing Oct 8, 2025 - Stock Titan
Biomea Fusion announces proposed public offering of securities - MarketScreener
Biomea Fusion, Inc. (BMEA) Stock: Volatile Surge Ahead of Jefferies-Led Equity Offering - parameter.io
Biomea's diabetes drug shows promise, may work for those not responding to GLP-1 - MarketScreener
Biomea announces positive 52-week results from phase II COVALENT-111 study in type 2 diabetes - MarketScreener
Biomea Fusion Reports Phase 2 Data in Diabetes, Launches Stock Offering - MarketScreener
Biomea Fusion Announces Proposed Public Offering of Securities - GlobeNewswire
Biomea Fusion launches public offering of common stock and warrants By Investing.com - Investing.com Australia
Biomea Fusion launches public offering of common stock and warrants - Investing.com India
Biomea Fusion reports 52-week results from Phase II diabetes trial - Investing.com
Biomea Fusion Reports Positive 52-Week Results from Phase II COVALENT-111 Study of Icovamenib in Type 2 Diabetes Patients - Quiver Quantitative
1.8% HbA1c reduction sustained at Week 52 — Biomea Fusion's icovamenib shows durable benefit - Stock Titan
Why Biomea Fusion Inc. stock remains undervaluedTrade Risk Summary & Safe Entry Zone Identification - newser.com
Visualizing Biomea Fusion Inc. stock with heatmapsVolume Spike & Weekly High Potential Alerts - newser.com
Biomea Fusion (NASDAQ:BMEA) Receives “Buy” Rating from D. Boral Capital - Defense World
BMEA: D. Boral Capital Maintains Buy Rating with $16 PT | BMEA S - GuruFocus
Biomea Fusion's (BMEA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
How geopolitical tensions affect Biomea Fusion Inc. stockShort Setup & Smart Money Movement Alerts - newser.com
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biomea Fusion, Inc. reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
48,000 Stock Options: Biomea Fusion Makes Key Inducement Grant Under 2023 Equity Plan - Stock Titan
What drives Biomea Fusion Inc stock priceExit Strategy Tips & Affordable Growth Investments - earlytimes.in
Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO - MSN
What Forward P E Multiple Suggests About Pritish Nandy Communications Ltds ValuationMarket Insider Reports & Low Entry Cost Investments - earlytimes.in
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):